SpectruMedix and Transgenomic Enter into Distribution Agreement in Europe

Complementary Genetic Analysis Platform Adds Depth to Transgenomic's Product Portfolio

21-Jan-2004

STATE COLLEGE, Pa., and OMAHA, Neb. - SpectruMedix LLC and Transgenomic Inc. announced that they have entered into an agreement for Transgenomic to distribute SpectruMedix's Reveal(TM) Genetic Analysis Systems in Europe. Transgenomic's European marketing organization will market, sell and service the SpectruMedix systems. The Reveal System is a multicapillary gel electrophoresis instrument. Its scalability to support high throughput genetic variation discovery and its DNA sequencing capability complement the Transgenomic WAVE(R) System's ability to detect low-abundance genetic variation and to purify DNA fragments of interest from mixtures of normal and variant DNA.

According to Collin D'Silva, Transgenomic CEO, "The quest by researchers to associate genetic variation with clinical or biological traits potentially requires multiple technologies depending on the specific situation. We are pleased to add SpectruMedix's Reveal platform as a complement to our own WAVE System." He concluded, "Our continuing objective is to provide an integrated array of solutions, both instruments and consumables, that are relevant to our customers' workflow."

In speaking about the selection of Transgenomic for its distribution needs, John W. Ritson, SpectruMedix President and CEO, stated, "We are impressed by Transgenomic's reputation among its customers for providing cost- effective solutions and quality service and support. We expect to benefit from Transgenomic's strong sales and marketing infrastructure in Europe as well as their existing customer base. This agreement represents a unique opportunity for SpectruMedix to complement the Transgenomic product line with our Total Genetic Analysis Solution portfolio. The agreement between our companies will allow us to address the current and growing needs in the European market."

https://www.bionity.com/en/news/33966/spectrumedix-and-transgenomic-enter-into-distribution-agreement-in-europe.html